ERNA

Ernexa Therapeutics Inc

May 18 • 04:00PM ET

12.25

-1.38 -10.12 %

Healthcare • Biotechnology • USA • Nano • NASD

May 15, 11:02 AMERNA-101 ovarian cancer preclinical success and momentum drive 24% ERNA surge on May 15.

Peers: GLMD BCDA TNXP BNTC PRQR

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-30.72	Insider Own	41.78%	Shs Outstand	1.17M	Perf Week	69.90%
Market Cap	14.29M	Forward P/E	-	EPS next Y	-1.18	Insider Trans	-	Shs Float	0.68M	Perf Month	135.80%
Enterprise Value	5.50M	PEG	-	EPS next Q	-	Inst Own	12.77%	Short Float	0.79%	Perf Quarter	48.44%
Income	-11.40M	P/S	-	EPS this Y	83.22%	Inst Trans	-	Short Ratio	0.00	Perf Half Y	-68.79%
Sales	0.00M	P/B	2.08	EPS next Y	87.42%	ROA	-145.97%	Short Interest	0.01M	Perf YTD	-59.17%
Book/sh	5.88	P/C	1.56	EPS next 5Y	74.56%	ROE	-2505.39%	52W High	93.75 -86.93%	Perf Year	-85.42%
Cash/sh	7.87	P/FCF	-	EPS past 3/5Y	73.56% 69.90%	ROIC	-160.72%	52W Low	3.18 284.87%	Perf 3Y	-98.79%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	51.80% 24.30%	Perf 5Y	-99.99%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	98.68%	Oper. Margin	-	ATR (14)	2.04	Perf 10Y	-99.99%
Dividend Ex-Date	-	Quick Ratio	2.89	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	66.06	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.89	EPS Q/Q	87.94%	SMA20	78.76%	Beta	2.26	Target Price	30.00
Payout	-	Debt/Eq	0.06	Sales Q/Q	-	SMA50	95.82%	Rel Volume	0.14	Prev Close	13.63
Employees	5	LT Debt/Eq	0.03	Earnings	-	SMA200	-49.20%	Avg Volume	1.64M	Price	12.25
IPO	Aug 29, 1991	Option/Short	No / No	EPS/Sales Surpr.	- -	Trades		Volume	233,863	Change	-10.12%

May-11-26 09:15AM	Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101 (GlobeNewswire)
May-06-26 10:40AM	Ernexa Therapeutics (ERNA) Preclinical Data Shows 100% Survival and Complete Tumor Clearance in Ovarian Cancer Models (InvestorsHub) +51.38%
10:30AM	BC-Most Active Stocks (Associated Press)
08:33AM	Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models (GlobeNewswire)
Apr-30-26 09:00AM	Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split (GlobeNewswire) -21.24%
08:55AM	Loading…
Mar-31-26 08:55AM	Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026 (GlobeNewswire) +5.29%
Feb-20-26 09:05AM	Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series (GlobeNewswire) -17.25%
Feb-06-26 09:25AM	Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering (GlobeNewswire) -44.66%
Feb-03-26 08:45AM	Ernexa Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA (GlobeNewswire) -25.80%
Jan-27-26 08:45AM	Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program (GlobeNewswire)
Jan-06-26 08:15AM	Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer (GlobeNewswire)
Dec-08-25 08:30AM	Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer (GlobeNewswire)
Dec-03-25 08:30AM	Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Dec-02-25 08:50AM	Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOG (GlobeNewswire)
Nov-11-25 07:00AM	Ernexa Therapeutics to Present at Oxford Global's Cell 2025 (GlobeNewswire) -5.39%
08:35AM	Loading…
Nov-10-25 08:35AM	Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials (GlobeNewswire)
Nov-06-25 09:15AM	Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor "What This Means" Platform (GlobeNewswire)
Oct-29-25 08:33AM	Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer (PR Newswire) +40.80%
Oct-01-25 08:30AM	Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa (GlobeNewswire)
Sep-29-25 08:30AM	Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit (GlobeNewswire)
Sep-17-25 08:30AM	Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research (GlobeNewswire) -5.22%
Sep-10-25 08:30AM	Ernexa Therapeutics Provides Update on Operational Excellence and Performance (GlobeNewswire)
Sep-03-25 09:30AM	Ernexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Jul-09-25 08:30AM	Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire)
Jun-25-25 08:30AM	Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development (GlobeNewswire) -5.05%
Jun-24-25 08:30AM	Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement (GlobeNewswire) -17.50%
Jun-11-25 09:35AM	Ernexa Therapeutics announces 1-for-15 reverse stock split (TipRanks)
Jun-10-25 09:30AM	Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split (GlobeNewswire) -17.99%
May-28-25 08:30AM	Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025 (GlobeNewswire)
May-14-25 08:30AM	Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations (GlobeNewswire) +13.11%
08:30AM	Loading…
May-08-25 08:30AM	Ernexa Therapeutics Announces Participation in the D. Boral Capital Inaugural Global Conference (Newsfile)
Apr-29-25 08:30AM	Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025 (GlobeNewswire)
Apr-22-25 08:30AM	Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025 (GlobeNewswire)
Apr-03-25 08:55AM	Ernexa Therapeutics Closes New Funding Round (GlobeNewswire) -5.24%
Mar-25-25 08:30AM	Eterna Therapeutics Changes Name to Ernexa Therapeutics to Reflect New Strategic Focus on Ovarian Cancer and Autoimmune Disease (GlobeNewswire) -5.77%
Feb-26-25 08:30AM	Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline (GlobeNewswire)
Jan-29-25 08:46AM	Eterna appoints Zeldis, Sather to scientific advisory board (TipRanks)
Jan-28-25 08:30AM	Eterna Therapeutics Announces Expansion of Scientific Advisory Board (GlobeNewswire)
Jan-14-25 08:30AM	Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer (GlobeNewswire) +48.22%
Jan-09-25 07:30AM	Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors (GlobeNewswire)
Dec-03-24 08:30AM	Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidate's (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer Models (GlobeNewswire) -9.95%
Nov-25-24 08:30AM	Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program (GlobeNewswire)
Nov-14-24 08:30AM	Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing (GlobeNewswire)
Oct-30-24 08:30AM	Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success (GlobeNewswire)
Oct-18-24 08:06AM	Eterna, Factor announce license, collaboration agreement (TipRanks)
Oct-17-24 08:00AM	Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases (GlobeNewswire)
May-14-24 10:53PM	ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q1 2024 (InvestorPlace) +9.81% -9.79%
May-10-24 08:00AM	Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases (GlobeNewswire) -6.48%
May-08-24 09:31AM	Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board (GlobeNewswire) +12.12%
May-07-24 08:00AM	Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on the Development of a mRNA-Engineered iPSC Line which Mimics Native B2M Expression, via Targeted Insertion of HLA-E at the B2M Locus (GlobeNewswire) +12.50%
08:00AM	Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases (GlobeNewswire)
Mar-15-24 08:53AM	ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q4 2023 (InvestorPlace)
Feb-20-24 08:30AM	Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors (GlobeNewswire)
Jan-03-24 04:15PM	Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4) (GlobeNewswire)
Dec-21-23 11:18AM	Eterna Therapeutics Appoints Sanjeev Luther as President and CEO (Exec Edge)
Dec-20-23 04:15PM	Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer (GlobeNewswire) +9.87%
Dec-14-23 06:56PM	Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing (GlobeNewswire) +29.29% -16.57%
Nov-02-23 11:48AM	Eterna Therapeutics Appoints Dr. James Bristol to Board of Directors (Exec Edge) +8.13%
Nov-01-23 08:30AM	Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors (GlobeNewswire) -12.76%
Sep-06-23 01:01PM	Eterna Therapeutics Teams with Lineage Cell on Transplant Therapies (Exec Edge)
09:40AM	EXCLUSIVE: Cell Therapy Player Lineage Cell Therapeutics Starts Development Activities Under Licensing Pact With Eterna Therapeutics (Benzinga)
08:00AM	Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell Therapeutics (GlobeNewswire)
Sep-05-23 11:24AM	Eterna Therapeutics Appoints Dorothy Clarke to Board of Directors (Exec Edge)
08:30AM	Eterna Therapeutics Appoints Biopharma Industry Veteran Dorothy Clarke to Board of Directors (GlobeNewswire)
Jul-18-23 02:24PM	Eterna Therapeutics Announces $8.7M Private Placement Transaction (Exec Edge) +8.89%
08:00AM	Eterna Therapeutics Announces Completion of $8.7 Million of Convertible Debt Financing (GlobeNewswire)
Jul-11-23 11:21AM	Eterna Therapeutics Appoints Industry Veterans Binder, Wagner to Board of Directors (Exec Edge) +6.52%
08:30AM	Eterna Therapeutics Appoints Biotech Industry Veterans Brant Binder and Richard Wagner, Ph.D. to Board of Directors (GlobeNewswire)
May-24-23 11:18AM	Eterna Therapeutics Appoints Megan Yung as CSO, General Counsel (Exec Edge) -5.41%
08:30AM	Eterna Therapeutics Appoints Megan Yung as Chief Strategy Officer, General Counsel (GlobeNewswire)
May-17-23 08:30AM	Eterna Therapeutics and Factor Bioscience Announce New Data on Multi-Cell-Type Therapeutic Approach at American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting (GlobeNewswire) -5.73%
May-04-23 08:30AM	Eterna Therapeutics to Deliver Eight Presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting (GlobeNewswire)
May-03-23 01:40PM	Eterna Therapeutics Buys Allogeneic Immuno-Oncology Platform from Exacis (Exec Edge)
May-02-23 07:30AM	Eterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform from Exacis Biotherapeutics (GlobeNewswire)
Apr-11-23 08:00AM	Eterna Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for Up To $10 Million (GlobeNewswire)
Mar-28-23 08:30AM	Jeff Karp, Ph.D., Joins Eternas Scientific Advisory Board (GlobeNewswire)
Mar-20-23 04:10PM	Eterna Therapeutics Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights (GlobeNewswire) -7.74%
Mar-16-23 07:04AM	Insiders might want to re-evaluate their US$2.7m stock purchase as Eterna Therapeutics Inc. (NASDAQ:ERNA) drops to US$16m (Simply Wall St.) +10.00%
Feb-22-23 09:46AM	EXCLUSIVE: Lineage Cell Inks Exclusive Agreement For Novel Cell-Based Therapies With Potential In Neurology (Benzinga)
08:00AM	Eterna Therapeutics Enters Into Option and License Agreement with Lineage Cell Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications (GlobeNewswire)
Jan-04-23 08:30AM	Eterna Therapeutics Appoints Matt Angel, Ph.D. as Chief Executive Officer and President (GlobeNewswire) +8.06%
Dec-20-22 08:05AM	In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Dr. Matt Angel, CEO Eterna Therapeutics (ACCESSWIRE)
Nov-01-22 08:30AM	Eterna Therapeutics Announces Research Collaboration to Develop Advanced Gene-Edited iPS Cell Therapies (GlobeNewswire)
Oct-18-22 08:30AM	Eterna Therapeutics to Present at iPSC-Derived Immunotherapies Congress (GlobeNewswire) +10.98%
Oct-17-22 08:30AM	Eterna Therapeutics Completes Name Change, Acquires Option to License iPSC-Derived NK and T Cell Therapies from Exacis Biotherapeutics (GlobeNewswire) +19.94%

Ernexa Therapeutics, Inc. engages in the provision of cell engineering therapies. It is involved in the development of mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. The company was founded in 1984 and is headquartered in Cambridge, MA.

CEOMr. Sanjeev Luther

Senior VP of FinanceMs. Sandra M. Gurrola

Chief Scientific OfficerDr. Robert Hamilton Pierce M.D.

General CounselMs. Dorothy J. Clarke

Senior Vice President of Technical Operations (Consultant)Dr. Kanika Chawla Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cherington Charles	10% Owner	Feb 10 '26	Buy	0.50	4,000,000	2,000,000	6,779,440	Feb 17 09:14 PM
Cherington Charles	10% Owner	Jun 09 '25	Buy	0.10	21,241,163	2,221,826	41,659,743	Jun 11 08:34 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ERNA

Ernexa Therapeutics Inc

Upgrade your Finviz experience